scholarly journals Pluripotent Stem Cells in Toxicity Testing: An Omics Approach

10.5772/63929 ◽  
2016 ◽  
Author(s):  
Smita Jagtap ◽  
Kesavan Meganathan ◽  
Vilas Wagh
Keyword(s):  
Stem Cells ◽  
Pluripotent Stem Cells ◽  
Toxicity Testing

scholarly journals SENSITIVE TOXICITY TESTING OF ART DISPOSABLES USING HUMAN PLURIPOTENT STEM CELLS

2020 ◽  
Vol 114 (3) ◽  
pp. e439
Author(s):  
Ye Yuan ◽  
Courtney Grimm ◽  
Rachel C. West ◽  
William B. Schoolcraft ◽  
Rebecca L. Krisher
Keyword(s):  
Stem Cells ◽  
Pluripotent Stem Cells ◽  
Toxicity Testing ◽  
Human Pluripotent Stem Cells

scholarly journals Bioengineering Clinically Relevant Cardiomyocytes and Cardiac Tissues from Pluripotent Stem Cells

2021 ◽  
Vol 22 (6) ◽  
pp. 3005
Author(s):  
Emma Claire James ◽  
Eva Tomaskovic-Crook ◽  
Jeremy Micah Crook
Keyword(s):  
Stem Cells ◽  
Heart Disease ◽  
Electric Fields ◽  
Pluripotent Stem Cells ◽  
Heart Development ◽  
Disease Patient ◽  
Toxicity Testing ◽  
Model Systems ◽  
Patient Specific ◽  
Cardiac Tissues

The regenerative capacity of cardiomyocytes is insufficient to functionally recover damaged tissue, and as such, ischaemic heart disease forms the largest proportion of cardiovascular associated deaths. Human-induced pluripotent stem cells (hiPSCs) have enormous potential for developing patient specific cardiomyocytes for modelling heart disease, patient-based cardiac toxicity testing and potentially replacement therapy. However, traditional protocols for hiPSC-derived cardiomyocytes yield mixed populations of atrial, ventricular and nodal-like cells with immature cardiac properties. New insights gleaned from embryonic heart development have progressed the precise production of subtype-specific hiPSC-derived cardiomyocytes; however, their physiological immaturity severely limits their utility as model systems and their use for drug screening and cell therapy. The long-entrenched challenges in this field are being addressed by innovative bioengingeering technologies that incorporate biophysical, biochemical and more recently biomimetic electrical cues, with the latter having the potential to be used to both direct hiPSC differentiation and augment maturation and the function of derived cardiomyocytes and cardiac tissues by mimicking endogenous electric fields.

Human neural microtissues derived from induced pluripotent stem cells for toxicity testing

2014 ◽  
Vol 229 ◽  
pp. S144
Author(s):  
David Fluri ◽  
Rosemarie Marchan ◽  
Wolfgang Moritz ◽  
George Kopitas ◽  
Jan G. Hengstler ◽  
...  
Keyword(s):  
Stem Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Toxicity Testing ◽  
Induced Pluripotent

Status and Use of Induced Pluripotent Stem Cells (iPSCs) in Toxicity Testing

2018 ◽  
pp. 199-212
Author(s):  
Min Wei Wong ◽  
Chris S. Pridgeon ◽  
Constanze Schlott ◽  
B. Kevin Park ◽  
Christopher E. P. Goldring
Keyword(s):  
Stem Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Toxicity Testing ◽  
Induced Pluripotent

scholarly journals Single Cell Sequencing and Kidney Organoids Generated from Pluripotent Stem Cells

2020 ◽  
Vol 15 (4) ◽  
pp. 550-556 ◽  
Author(s):  
Haojia Wu ◽  
Benjamin D. Humphreys
Keyword(s):  
Stem Cells ◽  
Single Cell ◽  
Pluripotent Stem Cells ◽  
High Throughput Screening ◽  
Kidney Development ◽  
Toxicity Testing ◽  
Human Kidney ◽  
Cell Types ◽  
Time Frame ◽  
Kidney Organoids

Methods to differentiate human pluripotent stem cells into kidney organoids were first introduced about 5 years ago, and since that time, the field has grown substantially. Protocols are producing increasingly complex three-dimensional structures, have been used to model human kidney disease, and have been adapted for high-throughput screening. Over this same time frame, technologies for massively parallel, single-cell RNA sequencing (scRNA-seq) have matured. Now, both of these powerful approaches are being combined to better understand how kidney organoids can be applied to the understanding of kidney development and disease. There are several reasons why this is a synergistic combination. Kidney organoids are complicated and contain many different cell types of variable maturity. scRNA-seq is an unbiased technology that can comprehensively categorize cell types, making it ideally suited to catalog all cell types present in organoids. These same characteristics also make scRNA-seq a powerful approach for quantitative comparisons between protocols, batches, and pluripotent cell lines as it becomes clear that reproducibility and quality can vary across all three variables. Lineage trajectories can be reconstructed using scRNA-seq data, enabling the rational adjustment of differentiation strategies to promote maturation of desired kidney cell types or inhibit differentiation of undesired off-target cell types. Here, we review the ways that scRNA-seq has been successfully applied in the organoid field and predict future applications for this powerful technique. We also review other developing single-cell technologies and discuss how they may be combined, using “multiomic” approaches, to improve our understanding of kidney organoid differentiation and usefulness in modeling development, disease, and toxicity testing.

Directed differentiation of mouse-induced pluripotent stem cells generates dopaminergic nerve

2010 ◽  
Vol 34 (8) ◽  
pp. S36-S36
Author(s):  
Ping Duan ◽  
Xuelin Ren ◽  
Wenhai Yan ◽  
Xuefei Han ◽  
Xu Yan ◽  
...  
Keyword(s):  
Stem Cells ◽  
Induced Pluripotent Stem Cells ◽  
Pluripotent Stem Cells ◽  
Directed Differentiation ◽  
Induced Pluripotent
Sign in / Sign up

Export Citation Format

Share Document